Improving the Stability of EGFR Inhibitor Cobalt(III) Prodrugs

[Image: see text] Although tyrosine kinase inhibitors (TKIs) have revolutionized cancer therapy in the past two decades, severe drawbacks such as strong adverse effects and drug resistance limit their clinical application. Prodrugs represent a valuable approach to overcoming these disadvantages by a...

Descripción completa

Detalles Bibliográficos
Autores principales: Mathuber, Marlene, Schueffl, Hemma, Dömötör, Orsolya, Karnthaler, Claudia, Enyedy, Éva A., Heffeter, Petra, Keppler, Bernhard K., Kowol, Christian R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2020
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7724630/
https://www.ncbi.nlm.nih.gov/pubmed/33222438
http://dx.doi.org/10.1021/acs.inorgchem.0c03083

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7724630/
https://www.ncbi.nlm.nih.gov/pubmed/33222438
http://dx.doi.org/10.1021/acs.inorgchem.0c03083

Ejemplares similares